journal
MENU ▼
Read by QxMD icon Read
search

Journal of Ocular Pharmacology and Therapeutics

journal
https://www.readbyqxmd.com/read/29148965/nonclinical-safety-assessment-of-anti-factor-d-key-strategies-and-challenges-for-the-nonclinical-development-of-intravitreal-biologics
#1
Vladimir Bantseev, Rebecca Erickson, Douglas Leipold, Caroline Amaya, Paul E Miller, Helen Booler, Evan A Thackaberry
PURPOSE: The nonclinical toxicology program described here was designed to characterize the safety profile of anti-factor D (AFD; FCFD4514S, lampalizumab) to support intravitreal (ITV) administration in patients with geographic atrophy (GA). METHODS: The toxicity of AFD was assessed in a single-dose and 6-month repeat-dose study in monkeys at doses up to 10 mg/eye. Toxicity was assessed by clinical ophthalmic examinations, intraocular pressure measurements, ocular photography, electroretinography, fluorescein angiography, optical coherence tomography, and anatomic pathology...
November 17, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29148864/morphologic-criteria-of-lesion-activity-in-neovascular-age-related-macular-degeneration-a-consensus-article
#2
Stefania Miotto, Nicola Zemella, Elena Gusson, Giacomo Panozzo, Sandro Saviano, Giuseppe Scarpa, Giorgio Boschi, Stefano Piermarocchi
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD). Individualized treatment regimens aim at obtaining the same visual benefits of monthly injections with a reduced number of injections and follow-up visits, and, consequently, of treatment burden. The target of these strategies is to timely recognize lesion recurrence, even before visual deterioration. Early detection of lesion activity is critical to ensure that clinical outcomes are not compromised by inappropriate delays in treatment, but questions remain on how to effectively monitor the choroidal neovascularization (CNV) activity...
November 17, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29111864/development-of-acyclovir-loaded-albumin-nanoparticles-and-improvement-of-acyclovir-permeation-across-human-corneal-epithelial-t-cells
#3
Panita Suwannoi, Mullika Chomnawang, Narong Sarisuta, Stephan Reichl, Christel C Müller-Goymann
PURPOSE: The aim of the present study was to develop acyclovir (ACV) ocular drug delivery systems of bovine serum albumin (BSA) nanoparticles as well as to assess their in vitro transcorneal permeation across human corneal epithelial (HCE-T) cell multilayers. METHODS: The ACV-loaded BSA nanoparticles were prepared by desolvation method along with physicochemical characterization, cytotoxicity, as well as in vitro transcorneal permeation studies across HCE-T cell multilayers...
November 7, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29111862/slit-lamp-based-ocular-scoring-systems-in-toxicology-and-drug-development-a-literature-survey
#4
Joshua Seth Eaton, Paul E Miller, Ellison Bentley, Sara M Thomasy, Christopher J Murphy
PURPOSE: To present a survey of the features of published slit lamp-based scoring systems and their applicability in the context of modern ocular toxicology and drug development. METHODS: References describing original or modified slit lamp-based scoring systems for human or veterinary clinical patients or in investigative or toxicologic research were collected following a comprehensive literature review using textbooks and online publication searches. Each system's indications and features were compiled to facilitate comparison...
November 7, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29099656/effectiveness-of-intracameral-phenylephrine-in-achieving-mydriasis-and-reducing-complications-during-phacoemulsification-a-systematic-review-and-meta-analysis
#5
Pedro Vazquez-Ferreiro, Francisco J Carrera-Hueso, Lidia Barreiro-Rodriguez, Marta Diaz-Rey, Jaime E Poquet-Jornet, María Auxiliadora Ramón-Barrios, Rafael Sanjuan-Cerveró
PURPOSE: To compare the effectiveness of intracameral phenylephrine and topical mydriatics in achieving mydriasis and protecting against complications during phacoemulsification. METHODS: A systematic search of the literature comparing the mydriatic effect and surgical safety profile of intracameral phenylephrine and topical mydriatics in phacoemulsification was conducted in the Medline, Embase, Lilacs, Web of Science, Cochrane, ClinicalTrials.gov , and Teseo databases...
November 3, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29064309/eyes-on-new-product-development
#6
Gary D Novack
No abstract text is available yet for this article.
October 24, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29022761/noninvasive-ocular-drug-delivery-system-of-dexamethasone-sodium-phosphate-in-the-treatment-of-experimental-uveitis-rabbit
#7
Kongnara Papangkorn, Eri Prendergast, John W Higuchi, Balbir Brar, William I Higuchi
PURPOSE: To investigate the efficacy and safety of dexamethasone sodium phosphate administered through Visulex system (DSP-Visulex) in treating experimental uveitis. METHODS: Uveitis was induced in rabbits by subcutaneous injections of complete Freund's adjuvant and an intravitreal injection of H37RA antigen. After induction, the animals of the control group received no treatment and the others received various treatment regimens of DSP-Visulex. Each regimen was different in DSP strength (4%, 8%, and 15%), application time, or treatment frequency...
October 12, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28953427/comparison-of-strategies-of-treatment-with-ranibizumab-in-newly-diagnosed-cases-of-neovascular-age-related-macular-degeneration
#8
Justus G Garweg, Sophie A Niderprim, Hanna Maria Russ, Isabel B Pfister
PURPOSE: In several case-studies improved outcomes have been reported after switching from a pro-re-nata (PRN)- to a treat-and-extend (T&E)-based therapeutic approach in cases of neovascular age-related macular degeneration (nAMD). We therefore wished to compare the effects of instigating 2 different protocols in newly-diagnosed nAMD undergoing treatment with Ranibizumab. METHODS: The outcomes of a PRN- and a T&E-based regime were retrospectively compared in treatment-naïve eyes under therapy with Ranibizumab for minimally 12 months in a routine clinical setting...
September 27, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28949790/the-effect-of-age-and-initial-central-retinal-thickness-on-earlier-need-of-repeat-ozurdex-treatment-for-macular-edema-due-to-retinal-vein-occlusion-a-retrospective-case-series
#9
Chun-Ju Lin, Huan-Sheng Chen, Cheng-Wen Su, Peng-Tai Tien, Jane-Ming Lin, Wen-Lu Chen, Chung-Yuan Kuo, Chun-Ting Lai, Yi-Yu Tsai
PURPOSE: To evaluate the effects of dexamethasone intravitreal implant (Ozurdex) and identify risk factors for repeated treatment in patients with macula edema due to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). METHODS: Patients followed up for at least 6 months were enrolled from 2013 to 2016. Dexamethasone intravitreal implant was given as the baseline treatment. For evaluation of dexamethasone intravitreal implant effects and complications, the demographics, medical history, best-corrected visual acuity (BCVA), intraocular pressure, and central retinal thickness (CRT) were recorded...
September 26, 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/29045169/use-of-topical-cannabinomimetic-palmitoylethanolamide-in-ocular-surface-disease-associated-with-antiglaucoma-medications
#10
Antonio Di Zazzo, Gloria Roberti, Alireza Mashaghi, Tulio Batista Abud, Daniela Pavese, Stefano Bonini
PURPOSE: Chronic use of topical hypotensive therapies in glaucoma patients leads to chronic inflammation of the ocular surface, which decreases the success rate of long-term glaucoma management. The aim of this study is to evaluate the effect of topical palmitoylethanolamide (PEA) (Defluxa(©)), a well-known anti-inflammatory and analgesic agent, in suppressing the ocular surface inflammation associated with the use of hypotensive eye drops. METHODS: In a pilot clinical trial, we enrolled 15 glaucomatous patients who received topical PEA (Defluxa) in addition to the current antiglaucoma drugs, while 15 glaucomatous patients did not receive any additional treatment...
November 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28956698/relevance-of-lipid-based-products-in-the-management-of-dry-eye-disease
#11
Jean-Sébastien Garrigue, Mourad Amrane, Marie-Odile Faure, Juha M Holopainen, Louis Tong
Components of the ocular surface synergistically contribute to maintaining and protecting a smooth refractive layer to facilitate the optimal transmission of light. At the air-water interface, the tear film lipid layer (TFLL), a mixture of lipids and proteins, plays a key role in tear surface tension and is important for the physiological hydration of the ocular surface and for ocular homeostasis. Alterations in tear fluid rheology, differences in lipid composition, or downregulation of specific tear proteins are found in most types of ocular surface disease, including dry eye disease (DED)...
November 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28945153/eyes-on-new-product-development
#12
Gary D Novack
No abstract text is available yet for this article.
November 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28933986/the-antiangiogenesis-effect-of-pirfenidone-in-wound-healing-in-vitro
#13
Xiao'an Liu, Yangfan Yang, Xiujuan Guo, Liling Liu, Kaili Wu, Minbin Yu
Abstracts Purpose: Pirfenidone is mostly used in antifibrotic and anti-inflammatory therapies. We have previously demonstrated that pirfenidone had antifibrotic and anti-inflammatory effects on the wound healing process after glaucoma filtration surgery in vitro and in vivo. Since the wound healing and reactive scarring process simultaneously involves inflammation, fibrosis, and angiogenesis, and angiogenesis plays a more important role in chronic or prolonged wound healing, we tried to explore the antiangiogenesis effect in pirfenidone and its potential multitarget function in regulating excessive scarring...
November 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28933582/dynamic-sensitivity-of-corneal-trpm8-receptors-to-menthol-instillation-in-dry-eye-versus-normal-subjects
#14
Peter Corcoran, David A Hollander, George W Ousler, Endri Angjeli, David Rimmer, Keith Lane, Mark B Abelson
PURPOSE: To assess the sensitivity of corneal cold receptors to a known transient receptor potential melastatin 8 (TRPM8) agonist, menthol, in dry eye and normals, and to determine whether factors such as disease duration or age affect responses. METHODS: Dry eye disease (DED) (N = 33) and normal (N = 15) subjects were randomly assigned to receive Rohto(®) Hydra (0.01% menthol) or Systane(®) Ultra treatments (OU) in a prospective, double-blind, crossover study...
November 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28922088/semifluorinated-alkane-eye-drops-for-treatment-of-dry-eye-disease-due-to-meibomian-gland-disease
#15
Philipp Steven, Albert J Augustin, Gerd Geerling, Thomas Kaercher, Florian Kretz, Kathleen Kunert, Johannes Menzel-Severing, Norbert Schrage, Wolfgang Schrems, Sonja Krösser, Michael Beckert, Elisabeth M Messmer
PURPOSE: Meibomian gland disease is generally accepted as the leading cause for evaporative dry eye disease (DED). In a previous study, perfluorohexyloctane, a semifluorinated alkane, has been demonstrated to significantly increase tear film breakup time and to reduce corneal fluorescein staining in patients with evaporative DED, thereby vastly reducing dry eye-related symptoms. This study was set up to evaluate perfluorohexyloctane in a larger population of patients with Meibomian gland dysfunction...
November 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28910175/neurotrophic-keratopathy-therapeutic-approach-using-a-novel-matrix-regenerating-agent
#16
Marta Guerra, Sara Marques, João Quadrado Gil, Joana Campos, Paula Ramos, Andreia Martins Rosa, Maria João Quadrado, Joaquim Neto Murta
PURPOSE: To evaluate the efficacy and tolerance of a new matrix-regenerating agent (RGTA), Cacicol(®), a polymer that mimics heparan sulfates bound to extracellular matrix proteins, avoiding its proteolysis, to treat neurotrophic keratopathy (NK). METHODS: Uncontrolled prospective clinical study performed between January 2014 and May 2016. Twenty-five patients (25 eyes) with corneal neurotrophic ulcers, nonresponsive to at least 2 weeks of conservative therapy, were treated with Cacicol, instilled once/twice a week...
November 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28961056/protective-effects-of-memantine-on-hydroquinone-treated-human-retinal-pigment-epithelium-cells-and-human-retinal-m%C3%A3-ller-cells
#17
Mohamed Tarek Moustafa, Claudio Ramirez, Kevin Schneider, Shari R Atilano, Gloria Astrid Limb, Baruch D Kuppermann, Maria Cristina Kenney
PURPOSE: Memantine (MEM) acts on the glutamatergic system by blocking N-methyl-d-aspartate (NMDA) glutamate receptors. The role that MEM plays in protecting retinal cells is unknown. Hydroquinone (HQ) is one of the cytotoxic components in cigarette smoke. In the present study, we tested whether pretreatment with MEM could protect against the cytotoxic effects of HQ on human retinal pigment epithelium cells (ARPE-19) and human retinal Müller cells (MIO-M1) in vitro. METHODS: Cells were plated, pretreated for 6 h with 30 μM of MEM, and then exposed for 24 h to 200, 100, 50, and 25 μM of HQ while MEM was still present...
October 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28854348/changing-initial-glaucoma-medical-therapy-increases-healthcare-resource-utilization
#18
Matthew G J Trese, Andrew W Lewis, Taylor S Blachley, Joshua D Stein, Sayoko E Moroi
PURPOSE: To determine the frequency and economic impact of changing initial glaucoma therapy for patients with newly diagnosed open-angle glaucoma (OAG) or ocular hypertension (OHT). METHODS: This retrospective longitudinal cohort study identified individuals within a large managed care network in the United States, who were newly diagnosed with OAG or OHT from 2001 to 2012 and were prescribed either a topical beta blocker (BB) or a prostaglandin analog (PGA). Claims data were analyzed over the 12-month period following their index prescription to determine physician prescribing habits, healthcare resource utilization patterns, and sociodemographic factors which may have contributed to changing the initial treatment strategy...
October 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28846481/effectiveness-of-combined-tear-film-therapy-in-patients-with-evaporative-dry-eye-with-short-tear-film-breakup-time
#19
Yung Hui Kim, Yeon Soo Kang, Hyo Seok Lee, Won Choi, In Cheon You, Kyung Chul Yoon
PURPOSE: The aim of this study was to evaluate the effectiveness of combined tear film therapy targeted to aqueous, mucin, and lipid layers in patients with refractory evaporative dry eye (EDE) with short tear film breakup time (TBUT). METHODS: The patients who had EDE with short TBUT and severe symptoms refractory to artificial tears were treated with hyaluronic acid (HA) 0.15% and diquafosol tetrasodium (DQS) 3% (Group 1), HA and carbomer-based lipid-containing eyedrops (Liposic EDO Gel, LPO) (Group 2), or HA, DQS, and LPO (Group 3)...
October 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28836880/long-term-intravitreal-dexamethasone-treatment-in-eyes-with-pretreated-chronic-diabetic-macular-edema
#20
Souska Zandi, Théo Lereuil, Florentina Freiberg, Maximilian Pfau, Isabel B Pfister, Christin Gerhardt, Stephan Michels, Laurent Kodjikian, Justus G Garweg
PURPOSE: The aim of this study is to assess the effect of repeated injections of dexamethasone implants in patients with persistent diabetic macular edema (DME) despite prior therapies. METHODS: This retrospective interventional study involved 47 DME-afflicted eyes, which were administered ≥2 intravitreal injections of dexamethasone. Group 1 (34 eyes) received a dexamethasone monotherapy, whereas group 2 (13 eyes) received a combination therapy with intravitreal antivascular endothelial growth factor as needed...
October 2017: Journal of Ocular Pharmacology and Therapeutics
journal
journal
32321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"